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Objectives. The primary objective of the International Vera-
pamil SR/Trandolapril Study (INVEST) is to compare the risk for
adverse outcomes (all-cause mortality, nonfatal myocardial infarc-
tion [MI] or nonfatal stroke) in hypertensive patients with
coronary artery disease (CAD) treated with either a calcium
antagonist-based or a noncalcium antagonist-based strategy.
Background. Treatment recommendations for hypertension
include initial therapy with a diuretic or beta-adrenergic blocking
agent, for which reductions in morbidity and mortality are
documented from randomized trials but are less than expected
from epidemiologic data. For this reason, recent attention has
focused on calcium antagonists or angiotensin-converting enzyme
inhibitors. While these agents reduce blood pressure, outcome
data from large randomized trials are lacking, but some case-
control data, dominated by short-acting dihydropyridines, suggest
an increased risk of cardiovascular events. These studies had
methodologic limitations and did not differentiate among calcium
antagonist types and formulations. Several studies differentiating
among calcium antagonist types and an overview of published
randomized trials show no increased risk with verapamil and
suggestion for benefit in CAD patients.
Methods. A total of 27,000 CAD patients with hypertension will
be randomized at 1,500 primary care sites to receive either a
calcium antagonist-based (verapamil) or beta-blocker/diuretic-
based (atenolol/hydrochlorothiazide) antihypertensive care strat-
egy. The study uses a novel, electronic “paper-less” system for
direct on-screen data entry, randomization and drug distribution
from a mail pharmacy linked to the coordination center via the
Internet.
Results. Contract negotiations with the United States and
international sites are ongoing. Patients being enrolled are pre-
dominantly elderly (72% aged 60 years or older) men (54%), with
either an abnormal coronary angiogram or prior MI (71%). In
addition to hypertension, CAD and elderly age, most patients
(89%) have one or more associated conditions (diabetes, dyslipi-
demia, smoking, cerebral or peripheral vascular disease, etc.)
contributing to increased risk for adverse outcome. While 26%
have diabetes, most of these are noninsulin dependent. Using the
protocol strategies, target blood pressures (according to JNC VI)
have been reached in 58% at the fourth visit, and as expected most
(89%) are requiring multiple antihypertensive drugs.
Conclusion. The design and baseline characteristics of the
initial patients recruited for a prospective, randomized, interna-
tional, multicenter study comparing two therapeutic strategies to
control hypertension in CAD patients are described.
(J Am Coll Cardiol 1998;32:1228–37)
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Hypertension and coronary artery disease (CAD) frequently
coexist as an important management problem, and the preva-
lence of this problem is likely to increase as our population
ages (1,2). Among over 5,000 contemporary outpatients with
angina pectoris cared for by primary care physicians, we found
that 58% also had hypertension and 65% required multiple
medicines (2). Diuretics and beta-adrenergic blocking agents
have been recommended as standard therapy for hypertension
because of reductions in stroke, heart failure, coronary heart
disease events and cardiovascular mortality (1,3–8). Yet reduc-
tions in coronary events have been consistently less than
predicted from epidemiologic studies based on blood pressure
reduction, and these reductions have plateaued in recent years
(1). So newer antihypertensive agents such as calcium antago-
nists and angiotensin-converting enzyme (ACE) inhibitors
have seen increasing use. While they have potential benefits in
patients with concomitant CAD (9–23), concern has arisen
over their safety because of lack of outcome data from
randomized trials. Some nonrandomized evaluations suggest
an increased risk of ischemic events with calcium antagonists
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(11–15) while others (including several randomized studies)
have not (16–20). Study methodology (e.g., case control,
retrospective analyses, meta-analyses) and type of calcium
antagonist (e.g., rapid release, short-acting dihydropyridines
vs. slow release [SR], long-acting or heart rate-controlling
agents) likely contribute to some of the risk differences re-
ported (21–29). The consensus is that until large randomized
trials demonstrate safety, caution should be used (at least with
rapid-release, short-acting, dihydropyridines) for patients with
hypertension and CAD (21,23,24,26,30–32).
However, verapamil has been shown effective and safe
alone or in combination in patients with hypertension and/or
CAD (19,33–43). Indeed, a recent overview of all published
randomized verapamil trials by one of us (C.J.P.) concluded
that in patients with CAD there was no evidence for harm and
considerable evidence to suggest benefit in those with recent
acute coronary syndromes (44). Yet it was acknowledged that
data were limited in patients with CAD and hypertension
(44–47). Randomized studies have also demonstrated that
ACE inhibitors reduce mortality in patients with left ventric-
ular dysfunction (48–52), acute myocardial infarction (MI)
(53) or heart failure (49), but randomized trial data on
outcomes are lacking in hypertension. A pilot study of com-
bined treatment with verapamil and trandolapril in patients
with stable angina and left ventricular dysfunction suggested
improved ventricular function and exercise capacity with re-
duction in angina (54). In post-MI patients, rates of reinfarc-
tion, unstable angina and readmission for heart failure were
lower with the verapamil–trandolapril combination compared
with trandolapril alone (54). However, neither of these studies
(54,55) was of sufficient size and duration to be definitive.
To address uncertainty regarding clinical outcomes with
antihypertensive treatment that includes a calcium antagonist,
large-scale randomized trials are necessary. Because data for
many of the reports of adverse outcomes with calcium antag-
onist therapy were based on outpatients treated by primary
care physicians, these trials should focus on a similar patient
population. As the diagnosis of CAD is often difficult to
exclude with certainty in hypertensive outpatients and the
adverse outcomes of interest are related to CAD, it would
seem reasonable to focus on the hypertension population with
evidence for coronary disease. Finally, because there is evi-
dence for safety with verapamil in patients with CAD, this
agent seems to be a rational choice.
The purpose of this article is to provide the design and
baseline characteristics of the patients being recruited for the
International Verapamil SR/Trandolapril Study (INVEST).
Methods
Study objectives. The primary objective of INVEST is to
examine the hypothesis that risk for adverse outcomes in
hypertensive CAD patients is at least equivalent during treat-
ment of hypertension initiated with a calcium antagonist-based
strategy compared with a beta-blocker/diuretic-based strategy.
Adverse outcomes are defined as all cause mortality, nonfatal
MI or nonfatal stroke. The calcium antagonist-based strategy
initiates treatment with either verapamil SR or the combina-
tion of verapamil SR and trandolapril for special populations
according to JNC VI (1). The noncalcium antagonist strategy
initiates treatment with either atenolol or hydrochlorothiazide
or the combination of one of these with trandolapril for special
populations. Special populations for INVEST are those with
poor renal functioning, diabetics and those with heart failure
due to systolic left ventricular dysfunction defined by an
ejection fraction ,40%. These strategies are representative of
two widely used strategies to treat patients with hypertension
and CAD in the primary care setting and are based on current
guidelines (1). Secondary objectives are to determine that
these strategies are at least equivalent in the control of blood
pressure, symptoms of myocardial ischemia and important
adverse experiences. Other objectives include assessing trends
for cancer, Parkinson’s disease, Alzheimer’s disease, autoim-
mune disease and gastrointestinal bleeding, as well as deter-
mining cost of cardiac care, quality of life and compliance.
Study design and patient selection. An international, mul-
ticenter, randomized clinical trial, INVEST uses a parallel
prospective design with two treatment arms. Patient eligibility
criteria include age 50 years or older, essential hypertension as
defined by the JNC VI (1) requiring drug therapy and docu-
mented CAD. Documented CAD is defined as any one of the
following: remote confirmed MI, abnormal coronary angio-
gram (.50% narrowing of at least one major coronary artery),
abnormalities on two different types of stress tests or diagnosis
of classical angina pectoris. All patients must be willing and
able to grant informed consent and the study must be approved
by appropriate review committees for the protection of human
subjects.
Exclusion criteria include unstable angina, angioplasty,
coronary bypass or stroke within the previous month; beta-
blocker use within the previous 2 weeks or previous year for
post-MI patients; sinus bradycardia, sick sinus syndrome or
atrioventricular block of more than first degree in the absence
of an implanted pacemaker; severe (New York Heart Associ-
ation class IV) heart failure; severe renal (creatine $4.0) or
hepatic failure; or contraindication to verapamil.
Study plan. Ambulatory hypertensive patients with CAD,
who qualify, are randomized to receive therapy with either the
calcium antagonist-based or a noncalcium antagonist-based
treatment strategy (Fig. 1). Those randomized to the calcium
Abbreviations and Acronyms
ACE 5 angiotensin-converting enzyme
CAD 5 coronary artery disease
INVEST 5 International Verapamil SR/Trandolapril Study
JNCVI 5 The Sixth Report of the Joint National Committee
on Detection, Evaluation, and Treatment of High
Blood Pressure
MI 5 myocardial infarction
SR 5 slow release
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antagonist strategy begin with verapamil SR (Isoptin SR; Knoll
AG, Germany) 240 mg/daily, and those randomized to the
noncalcium antagonist strategy begin with atenolol 50 mg/
daily. These doses can be adjusted downward by the physician
if needed. Additional drugs (trandolapril [Mavik, Knoll AG,
Ludwigshafen, Germany] and hydrochlorothiazide) are added
in either strategy when needed either for special populations or
to reach the target blood pressure. When trandolapril is
needed in the calcium antagonist strategy, it is supplied as the
verapamil SR/trandolapril combination (Tarka, Knoll AG,
Ludwigshafen, Germany). The target blood pressure is defined
as a mean of two sitting cuff blood pressure measurements
,140/,90 mm Hg or ,135/85 mm Hg for special populations.
Nonprotocol antihypertensive drugs may be added if needed to
reach target pressures provided that the calcium antagonist is
retained in the calcium antagonist strategy and a calcium
antagonist is not added in the noncalcium antagonist strategy.
In addition, the general care in both treatment strategies
will be in accordance with the nonpharmaceutical guidelines
provided in JNC VI (1). These are available to the patient as
printed instructions from the INVEST on-line system and
include nurse counseling in tobacco, caffeinated beverages and
alcohol. Instructions for secondary prevention of atherosclero-
sis complications are also standardized according to the Na-
tional Cholesterol Education Program (NCEP-2).
Patients are to return for follow-up visits 6, 12, 18, 24, 52, 78
and 104 weeks after their randomization visit and at the close
of the study. At each visit, response to treatment, occurrence of
symptoms (e.g., angina frequency or those related to a poten-
tial adverse outcome), a brief physical exam including blood
pressure and heart rate, and compliance are assessed. Changes
in medication or dosage as per the protocol (Fig. 2) are made
as necessary during follow-up to reach target blood pressure or
minimize unacceptable adverse experiences should they occur.
Serious outcomes such as death, nonfatal MI and nonfatal
stroke are to be reported within 24 h to the INVEST Admin-
istrative Coordinating Center. These events and pertinent
patient documents are reviewed by an Event Committee
masked to treatment assignment (Appendix 1). Treatment and
follow-up are expected to last 2 to 3 years, with final visits for
the last enrolled patients occurring at the end of the year 2000.
Study phases. Prior to enrollment of any patients, a prepi-
lot stage was conducted using mock patients to test the study
electronic system and recruit pilot sites. The active treatment
stage then consisted of a pilot phase and a full-scale phase. The
purpose of the pilot phase was to observe the electronic system
under actual study conditions, which included ordering and
dispensing study medications to enrolled patients. This plan
provided time to interrupt enrollment to make any system
changes that might be deemed necessary before the full
complement of study sites were on line. During the pilot phase,
160 patients from 30 sites in various geographic regions
throughout the United States were randomized.
Novel organization features. This study has many novel
organizational features. For example, in contrast to the usual
organization of a clinical trial in which a limited number of
Figure 1. Diagram of INVEST plan. Patients are randomized (R) at
visit 1 (0) to either a calcium antagonist antihypertensive care strategy
(bottom) or the noncalcium antagonist antihypertensive care strategy
(top). Initial study drug assignments would include verapamil SR or
atenolol, respectively. The doses provided are recommended but can
be modified by the prescription on the basis of the physician’s
knowledge of the patient’s condition (see Fig. 2). The patient’s return
for follow-up titration visits (T) at 6, 12 and 18 weeks, when additional
drugs or doses can be utilized as outlined. ( ) shows maximal dose of
trandolapril offered.
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investigators enroll many patients, the 27,000 patients in
INVEST will be drawn from approximately 1,500 primary care
site physicians with each physician enrolling about 15 to 20
patients. These physicians (site investigators) report to 156
local specialists who serve as specialist investigators for their
geographic area. Worldwide, these local specialist investigators
in turn report to opinion leaders in various geographic regions
who serve as regional directors and members of the Interna-
tional Steering Committee for INVEST. Overseeing the study
is the Principal Investigator and Executive Committee. An
independent Data and Safety Monitoring Committee (Appen-
dix 1) serves in an advisory capacity to the Steering Committee.
Also, INVEST is the first international randomized trial
completely designed for and conducted via the Internet. The
operational structure for data collection and handling allows
rapid enrollment of the numerous investigators and patients
necessary to complete the study. In particular, INVEST utilizes
the Internet for patient enrollment, randomization, drug pre-
scription and tracking of patient data (Fig. 3). All sites are
supplied with a personal computer configured with local
Internet access. Use of computer technology allows site phy-
sicians to not only enroll patients very quickly, but also receive
immediate notification electronically of the assigned random-
ized treatment strategy for the patient during the initial visit.
The system allows the site physician to customize the patient
prescription, in terms of dosing and additional drugs, with a
special section for computerized prescribing (Fig. 2). When the
completed prescription is verified by the physician, an elec-
tronic signal is sent to the pharmacy coordinating center and
study medications are dispensed from a central mail order
pharmacy that receives the prescription and patient informa-
tion electronically at the time of the visit. Patients receive their
medication within 7 days and return a bar-coded postcard or
call a toll-free phone number to confirm receipt of the
medication. On follow-up visits, patient information is entered
into the computer at the time of the visit and transmitted
electronically to the data coordinating center as well as the
pharmacy center for medications.
All facets of study operation, including study management,
randomization, titration and dispensing of study medications,
patient data access, and study monitoring are, therefore, part
of the INVEST Internet-based electronic system. Among the
advantages of this system are rapid data collection and man-
agement procedures, simplified data handling, reduction in
data errors, immediate responses to requests and more timely
generation of data summaries and study results. Advantages of
computerized prescribing and dispensing of study medications
for research purposes include the fact that prescription infor-
mation is legible and does not have to be transcribed by the
pharmacy, prescriptions are actually filled and prescriptions
are processed, filled immediately and shipped directly to the
patient. All of these actions are secured by unique password
protection for the physicians and high-level encryption. The
INVEST System Description is summarized in Appendix 2.
Sample size considerations. The hypothesis to be tested is
that the two initial antihypertensive treatment strategies are
equivalent. With 13,500 patients in each treatment strategy
arm, the confidence interval for risk is 615%. The sample size
Figure 2. Example of INVEST study drug titration
screen. The calcium antagonist care strategy titration
screen is shown with the protocol-recommended dose of
verapamil SR at randomization. The physician has the
option of modifying the dose according to those shown.
Once verified, the physician clicks the submit icon at the
bottom left, and the patient’s instructions as they will
appear on the label are printed in the box. An electronic
signal is sent to the database core to record the drug
dose and strategy assignment and also to the mail order
pharmacy to initiate distribution of study drug to the
patient. A similar titration screen appears for the non-
calcium antagonist strategy drugs (not shown).
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of 27,000 patients is adequate to detect a 20% difference in
event rates, if one exists, with power ranges and alpha outlined
below. From the literature only sparse data are available on the
event rates to be expected in the patient population targeted by
INVEST. In the APSIS trial, hypertensive patients with stable
angina had a combined rate for death and nonfatal MI of 3.4%
per year (46). In the Quinapril Ischemic Event Trial (QUIET),
the yearly rate for nonfatal MI in patients with CAD and
hypertension was 1.8% to 2.1% depending on the treatment
group, whereas the yearly death rate in both groups was only
0.7% (C. Pepine, personal communication, 1997). In patients
with hypertension and CAD, the Framingham study revealed
age- and gender-dependent 2-year mortality rates ranging from
0% (,50 years old) to 26% (C. Pepine, personal communication,
1997).
As the inclusion criteria of INVEST exclude very high-risk
patients, a yearly event rate for death, MI or stroke of 1.7% to
2.0% is expected. This is believed to be a conservative esti-
mate. Assuming a total of 27,000 patients (13,500/treatment
strategy), 10-month accrual period, a fraction of 10% of
patients to be censored and a (two-tailed) significance level of
5%, the power will range from 91.2% (yearly event rate 5
2.0%) to 86.4% (yearly event rate 5 1.7%).
Results
Full-scale site recruitment and patient enrollment began in
January 1998. A total of 701 sites are under contract as of
August 1998. In addition to the United States, sites are on line
in Australia, New Zealand and Germany, with Canada, Mex-
ico, Italy, France, Spain, Israel and South Africa scheduled
shortly. Baseline data on patient characteristics of age,
gender, race, concomitant disease and self-report quality of
life are summarized for the first 1,500 patients enrolled
(Table 1).
The patients being enrolled are predominantly elderly
(72% aged 60 years or older) males (54%), with either an
abnormal coronary angiogram or prior MI (71%). The major-
ity had a history of smoking (54%). In addition to hyperten-
sion, CAD and elderly age, most patients (89%) had one or
more associated conditions (diabetes, dyslipidemia, smoking,
cerebral or peripheral vascular disease, etc.) that contribute to
increased risk for adverse outcome. A total of 27% have
diabetes and most of these are noninsulin dependent. Inter-
estingly, 26% reported their health quality at entry as only fair
or poor.
Target blood pressures within guidelines using study drug
therapy have been achieved by 58% of those reaching their
Figure 3. Boxes on left show various steps at
the study site. Notations on right indicate role
of the INVEST on-line system in the step
(from top to bottom). The system provides
physicians with the electronic version of the
protocol and appropriate references (e.g., JNC
VI, links to medical data sources, etc.) to
familiarize physicians with the project. The
database core controls all data, checks for
correctness and determines whether the pa-
tient is eligible by comparing data entries made
during the first visit with eligibility criteria.
Randomization assigns initial study medication
strategy. Titration screen presents physicians
with protocol-specific options regarding study
medications. Physicians determine final pre-
scription. The drug notification system relays
final prescription to the drug distribution cen-
ter to dispense medications and mail to the
patient. The system schedules and prints out
follow-up visit within protocol-specified win-
dow and medication expected in the mail.
When the patient returns for follow-up visits,
the database core assures that all data values
entered are acceptable. Should the patient
require change in treatment according to pro-
tocol, medications are titrated by the database
core and options are presented to the physician
by the titration core. In a manner similar to
that of first visit, the physician modifies medi-
cations within protocol boundaries and the
prescription is generated, verified by the physi-
cian and forwarded to the drug distribution core.
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fourth visit. As expected, most (89%) are requiring multiple
antihypertensive drugs.
Discussion
The treatment of patients who have both hypertension and
CAD is a major concern for physicians worldwide, particularly
because safety data for calcium antagonists from randomized
controlled trials are lacking. Clearly more data are needed on
the effects on these agents on adverse outcomes. This study will
make a major contribution toward resolving the issue. In its
stepped-care strategy approach to the management of hyper-
tension, INVEST will compare the adverse outcomes observed
with treatment initiated using the calcium antagonist, vera-
pamil, with that observed using treatment initiated with the
beta-blocker, atenolol in patients with CAD. To date,
INVEST, with 13,500 patients in the calcium antagonist strat-
egy, will represent the largest calcium antagonist exposure yet
undertaken to determine the safety and efficacy of this form of
treatment. (Table 2).
The organizational structure and conduct of INVEST is
unique. The study is a “paper-less” international multicenter
study using a novel electronic system for direct on-screen data
entry, randomization and drug distribution from a central mail
order pharmacy, all linked via the Internet. The on-line
electronic data system simplifies patient entry and data han-
dling and should reduce errors and increase the speed with
which data can be produced. The integrated central drug
distribution system controls drug dispensing. The integration
of central drug assignment and distribution should prevent
unauthorized access to drugs, eliminate assignment errors and
generally simplify the process of titration dispensing, and
monitoring of patient compliance. Thus, in addition to its sites
and international scope, the INVEST design mimics standard
clinical practice and is believed to be a forerunner of clinical
trial research for the future.
Conclusion. Data on adverse outcomes during calcium
antagonist treatment of hypertension are lacking. Studies with
verapamil have shown beneficial effects on ischemic events and
mortality in patients with CAD. To resolve uncertainty related
to the effects of calcium antagonists on adverse outcomes in
patients with hypertension and associated conditions, large-
scale trials are necessary. The International Verapamil SR/
Trandolapril Study is an ongoing randomized controlled trial
of 27,000 CAD patients with hypertension designed to provide
data to help address this uncertainty.
Appendix 1
Administrative Center: C. Pepine (Project Director and Principal
Investigator), E. Handberg-Thurmond (Project Coordinator), R.
Cooper-DeHoff (Pharmacy Coordination), R. Kolb, J. Mitchell (Ad-
ministration and Technical Support), P. Zilles (Consultant); Data
Coordinating Center: R. Marks (Project Biostatistician), M. Conlon
Table 1. Patient Characteristics (%)
Age (yrs)
50–59 28
60–69 32
70–79 31
80–89 9
90–99 1
Gender
Female 46
Male 54
Race
African-American 23
Asian 1
Caucasian 73
Hispanic 3
Other 1
Medical history
Smoking (ever) 54
Current smoking (last 30 days) 15
Diabetes 26
Dyslipidemia 59
Renal insufficiency 3
Cancer 5
Cardiovascular history
Prior myocardial infarction (MI) 42
Abnormal coronary angiogram 54
Abnormal coronary angiogram or prior MI 71
Abnormal stress tests 20
Angina pectoris 54
Prior unstable angina 20
Coronary angioplasty 23
Coronary artery bypass graft (CABG) surgery 26
CABG or angioplasty 43
Arrhythmia 10
Pacemaker 3
Heart failure (,class IV) 6
Left ventricular hypertrophy 14
Prior stroke 7
Transient ischemic attack (TIA) 4
Prior stroke or TIA 9
Peripheral vascular disease 11
Reporting of self-health
Excellent 11
Good 63
Fair 23
Poor 3
Table 2. Randomized Trials Evaluating Calcium Antagonists for
Hypertension and/or Coronary Artery Disease
Study Calcium Antagonist Number of Patients
ALLHAT Amlodipine 40,000*
ASCOT Amlodipine NA
INSIGHT Nifedipine 7,300
ACTION Nifedipine 6,600
NORDIL Diltiazem 12,000
HOT Felodipine 19,200
STOP II Felodipine 6,600
SYST-EUR Nitrentidipine 4,695
CONVINCE Verapamil 15,000
INVEST Verapamil SR 27,000
*Study has four treatment arms.
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J. Birge, J. Bishop, N. Bittar, L. Blacher, A. Blanchard, J. Boak, J.
Boerner, M. Boland, L. Bonavita, R. Bond, J. Bonnano, J. Borkovec,
K. Boyer, P. Bradley, A. Brandau, T. Brill, H. Brodsky, D. Browder, N.
Brown, S. Brown, R. Browning, E. Bryce, M. Buchbinde, A. Buhr, W.
Bullock, J. Butler, D. Byler, C. Bynum, JF. Cadet, G. Caine, W.
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Deering, J. DeLuca, A. Delwadia, C. Demas, G. Dennish, V. DeQuat-
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Eupierre, H. Evans, R. Evans, S. Evans, J. Farjat, J. Farrell, J.
Faulkner, J. Feeman, D. Felker, D. Feller, T. Ferguson, J. Fidelholtz,
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Halkos, J. Hall, J. Hall, K. Hall, V. Hall, S. Halpern, C. Hamburg, R.
Hanlon, S. Hanna, G. Harman, A. Harrow, G. Hayes, M. Headley, R.
Heckey, C. Heinsen, G. Held, T. Hemmapl, J. Heneisen, M. Hen-
riquez, E. Heurich, D. Heyerdahl, C. Hill, D. Hill, J. Hill, R. Hill, D.
Hilliard, M. Hogenson, M. Holland, I. Holman, L. Hong, J. Hood, S.
Horowitz, M. Horseman, R. Hughston, Y. Imamura, D. Irwin, P.
Isbell, T. Ishimori, P. Jacobson, G. Jagan, K. Jahn, J. Jaikishen, G.
Jarrard, M. Jenkins, M. Jones, M. Jones, W. Jones, J. Joshi, J. Kagan,
B. Kaminski, S. Kanner, M. Kantzler, J. Karas, P. Karim, R. Karl, A.
Karns, R. Karns, R. Karody, J. Karrasch, R. Kasmikha, D. Katz, S.
Katzman, S. Kaveh, A. Kejriwal, R. Keller, H. Kempe, R. Kerensky, N.
Kerin, W. Kerr, S. Kestin, A. Khan, M. Khan, R. Khan, R. Khant, K.
Khooblall, I. Khurana, J. Kinahan, L. King, G. Kini, R. Kirstein, C.
Koeppl, R. Kohn, D. Kondos, L. Korman, G. Koshkaria, G.
Kotlewski, M. Kozinn, W. Kracht, A. Krepostm, D. Kresnicka, M.
Kumar, K. Kundlas, M. Kuttappan, E. La Kier, A. Lachman, N.
Lamarche, R. Landefeld, E. Lanear, J. Lang, L. Larson, N. Laufer, R.
Lee, R. Lee-Pack, B. Lemke, R. Lepiane, G. Lessmann, D. Leszkowit,
R. Leverence, J. Levine, R. Levine, C. Li, G. Limandri, B. Lipschutz,
A. Liu, Jr., D. Loew, J. Lousteau, R. Lucke, B. Lumicao, J. Lynch, J.
Maddi, M. Mahjoub, P. Malen, R. Malhotra, J. Mallett, D. Mangum,
R. Mann, S. Mareburg, S. Margolis, V. Marino, T. Marshall, W.
Martin, F. Martinez, M. Martinez, W. Mashman, A. Masood, M.
Masroor, S. Mathan, M. Mathur, C. Mattina, A. Mauskar, T. May III,
T. Mayer, B. McCarroll, L. McCauley, J. McCoy, P. McCulloug, T.
McKnight, A. McLaren, B. McLean, J. Medina, R. Mehra, J. Mehta, J.
Mehta, A. Meier, R. Mella, M. Mendizabal, R. Merrill, F. Messerli, B.
Messinger, D. Meyer, R. Michal, R. Michels, S. Mihyu, R. Miles, J.
Millan, J. Miller, P. Miller, T. Mills, J. Minnich, J. Mitchell, R.
Mitchell, C. Mock, K. Modi, R. Mohr, T. Monitz, S. Monroe, M.
Montrichar, A. Moosvi, R. Moran, M. Moreno, R. Morgan, L.
Morris, M. Moses, G. Mosquera, J. Mourad, M. Mrzyglocki, A. Munis,
J. Myers, R. Myers, S. Myers, J. Nadeau, M. Nadeemul, L. Nadgir, R.
Nair, S. Najar, D. Najman, P. Nalos, V. Namiredd, R. Nasr, A.
Naumovic, A. Nautiyal, D. Nemetz, S. Newaz, N. Nguyen, T. Nguyen,
R. Noel, B. Norton, G. Novak, J. Nunnelee, O. Nwabara, W. Nyitray,
J. Nystrom, M. Oefelein, R. Oglesby, G. Okonski, S. Ong, V. Oren-
dain, T. Ostrowski, R. Palmer, P. Parikh, S. Park, B. Patel, H. Patel, P.
Patel, S. Patel, S. Patel, T. Patel, R. Pathapati, H. Patton, K. Paulus, H.
Payne, W. Pearce, M. Pearson, S. Pennal, N. Perlman, D. Perry, J.
Perry, F. Petersen, T. Petry, C. Pettus, S. Philip, A. Phillips, O.
Pickus, N. Pierson, G. Pimentel, P. Pitroda, P. Platzer, L. Pluta, D.
Pocock, S. Podnos, T. Poe, M. Pond, P. Popper, M. Poss, P. Potu, J.
Prasad, S. Prasada, N. Premsingh, D. Pritchard, H. Punzi, W. Qazi, V.
Rajput, JC. Ramirez, A. Rao, T. Rashid, M. Rattinger, S. Raubort, W.
Rawlings, M. Ray, T. Raymond, A. Rayner, T. Razdan, M. Reddy, M.
Reddy, V. Reddy, E. Reh, R. Remler, T. Retta, L. Reyes, L. Reznick,
W. Rhodes, L. Rink, F. Rivers, M. Rivera, T. Rizzo, A. Robb, J.
Roberts, R. Rodriguez, M. Romeo, H. Rose, M. Rosenbloo, L.
Rosenfield, P. Rosman, D. Ross, E. Ross, D. Rothman, J. Routh, JA.
Roye, M. Rubin, P. Rubin, L. Rupp, H. Sabbota, H. Sacks, M.
Saklayen, J. Salberg, A. Samadani, M. Samalik, W. Sampson, S. Samy,
S. Sanchez, S. Sanchez, B. Sandoval, B. Sangani, J. Saponaro, C.
Saraiya, R. Sarma, D. Sauers, S. Savran, P. Sawrey, S. Schabelm, A.
Schachter, N. Scharff, C. Schearer, D. Scheer, R. Schellenb, A.
Schimmel, S. Schmidt, J. Schmitz, R. Schofield, A. Schonber, M. Schor,
B. Schrager, M. Schwarta, F. Schwartz, L. Schwartzb, M. Schwarze, J.
Schyberg, C. Scott, M. Scott, E. Searcy, RM. Sears, G. Sehapaya, P.
Seigel, H. Semler, F. Sessoms, S. Sexter, A. Shah, A. Shah, D. Shah, G.
Shah, H. Shah, S. Shah, S. Shahab, M. Shaker, O. Sharma, K.
Sheikh, M. Sherman, M. Shoop, A. Simpson, L. Sinatra, W. Sine, G.
Singh, J. Singh, S. Singh, S. Singh, V. Singh, G. Sinha, M. Sinha, D.
Slater, R. Smith, T. Smith, G. Snyder, A. Somers, C. Sparks-Ar, R.
Sparling, D. Spigner, S. Spivey-Mil, J. Spruill, J. Sraow, R. Starritt, R.
Steinberg, J. Stern, M. Stiles, J. Stokes, R. Stoltz, J. Stone, D. Stout, E.
Struik, B. Stryjewsk, D. Subich, L. Sukienik, W. Sullivan, R.
Sweeney, M. Tachman, J. Tanner, R. Tate, M. Taylor, A. Teklinski, H.
Tettamanti, H. Tjoa, R. Toban, S. Toloyan, B. Tome, B. Tran, T.
Tran, N. Trehan, P. Trentham, H. Trivedi, N. Tucker, S. Turner, M.
Tyler, C. Ulrich, J. Valdez-Gu, S. Varela, S. Varma, G. Vasquez, G.
Vellanikar, A. Villacastin, J. Voelz, W. von Ohlen, C. Voss, D. Vyas,
A. Wagner, E. Wahley, D. Walker, L. Walker, T. Wallace, W.
Wallizada, L. Walter, S. Wan, D. Watenber, J. Wassenaa, M. Was-
serm, L. Weaver, D. Webber, R. Weiderhol, R. Weiss, R. Weiss, S.
Wesonga, F. Westmeye, D. White, R. Whitman, B. Williams, D.
1234 PEPINE ET AL. JACC Vol. 32, No. 5
CAD PATIENTS WITH HYPERTENSION November 1, 1998:1228–37
Williams, J. Williams, M. Williams, J. Wilson, J. Wilson, Jr., J.
Winegar, E. Witt-Bockl, L. Wojonowi, W. Woody, J. Wortman, E.
Wozniak, J. Wright, R. Wyndham, S. Yaddanap, G. Yearwood, P. Yee,
K. Yehyawi, T. Yetil, D. Yorro, S. Young, K. Zaveri, S. Zellner, J.
Zizzi, B. Zuberi, F. Zugibe, L. Zukerman, N. Zukkoor, J. Zuniga-Se,
D. Zwicke.
SPECIALIST Investigators
Appendix 2: INVEST System
Description
This study uses a unique Internet-based patient data management
system developed at the University of Florida. The system uses web
technology, database technology, encryption and authorization in
accordance with FDA draft guidelines for clinical trial software and for
use of electronic signatures.
Data entry is restricted to authorized users and is encrypted. Data
elements are validated at entry in real time. Authorization restricts
access only to appropriate patient information and functions. Study
investigators, regional directors and study investigator staff members
have different levels of authorization and access. Regional manage-
ment summaries are available on line, over the Internet, in a secure
fashion providing immediate access of up-to-the-minute summaries of
regional activity. On-line trial management reports are available to
authorized users, up to date and around the clock.
Eligibility forms must be completely and correctly filled out before
randomization. Randomization is automated 24 hours a day, 7 days a
week from around the world with appropriate security and failsafe
mechanisms. On-line titration of study medications enables site phy-
sicians to practice within the parameters of the protocol. Limited
choices consistent with randomization preserve important features of
the protocol while allowing the participating physicians choices over
medications and dosages.
Security. Security is achieved by restricting access to all Internet
material to authorized users only, using state-less mechanisms to
ensure appropriate page access and by encrypting all transmissions.
Secure socket layer Level 3 security is performed using RSA 40-bit
encryption (international standard). The INVEST system uses a
Netscape Enterprise server with a Verisign Certificate of Authentica-
tion to provide encryption of all material moving to and from the
central web server. All study data are stored on a machine behind a
firewall from the Internet server, thereby restricting direct Internet
access by anyone other than authorized users. The servers and data are
physically secured and data are backed up off-site as part of the
recovery plan.
Each site physician investigator, specialist investigator, regional
director or other trial participant is issued a user identification (user
ID) and password for the purpose of conducting study-related activi-
ties over the Internet. These passwords are tied to authorized actions
and subsets of data. For example, a site physician would have authority
to enter eligibility data, randomize subjects, enter follow-up data and
review case listings, but would not have access to trial summary data or
data from other sites.
Trial management. The office of the Principal Investigator (PI)
authorizes all access to the system. A management database stores
contact information for all study participants as well as their autho-
rized levels of access. Levels of authorization and authorized contacts
are kept up to date by staff. Requests for interaction with the data
system coming from Internet sites are checked against the manage-
ment database to ensure that only authorized users can access study
materials and then only materials appropriate to their role in the study
(site investigator, specialist investigator, regional director, study man-
ager). The management database is maintained using the same
Internet technology as all other study data.
Contingency planning. Site computing system. The most likely point
of failure is the individual site computing system—the machine and
software system used by site staff. The contingency plan for site
computing system failure involves a direct long distance phone line to
the PI office where site staff can call between 8 am and 5 pm their local
time (somewhat fewer hours for European sites) Monday through
Friday. This is manned by PI staff members who will be authorized to
enter eligibility data and randomize the subject. Return receipt fax will
be used to document the assigned treatment arm. Should the system
fail for hardware reasons, the site can contact the authorized mainte-
nance provider (DELL Computer). Should the system fail for software
reasons, the administrative center will send a “rescue CD” containing
all the software used in the INVEST system. The rescue CD will
reinstall all software and reset the site system to the condition in which
it was originally received.
Site Internet service provider (ISP). The site computing system may
be operating normally, but their local ISP may not be operational. In
this case, the site can use the phone methods previously described. The
ISP for INVEST is IBM Global Network. IBM can be contacted to
help resolve local Internet access issues.
Internet Backbone. Occasionally, transient difficulties delay trans-
missions within regions. The backup phone methods can be used if
INVEST transactions must be performed during such a delay.
Web Server. The web server is protected by a SUN Microsystems
maintenance contract requiring service within 2 h and full repair within
24 h. An alternate web server can be put on line using existing
hardware within 4 h by on-call INVEST data management team. A
RAID level 5 disk mirroring system is used to provide redundant hot
swappable disk storage. Disk failure is the most common form of
system failure, and the RAID system ensures that there would be no
loss of service for simple drive failure. The system will automatically
switch to a mirrored back-up drive with no loss of service. The failed
drive can be removed from the system and replaced with a functional
drive without having the web server brought down.
Database server. The database server is also to be equipped with a
RAID level 5 disk mirroring system to ensure smooth operation in the
event of a disk failure. In the event of system failure, the entire
database server can be replaced with existing hardware within 4 h by
on-call INVEST data management team. A study manual for sites is
available both on line and in paper format describing the use of the
Internet and how it is used to support all data coordination activities of
INVEST. A user manual for interacting with INVEST via the Internet
is included. A public area of the INVEST web site (http://
invest.biostat.ufl.edu) provides information to the general public about
the trial.
All participant areas of the Internet are password restricted as
previously described and encrypted (RSA 40 bit) during all transmis-
sions. In areas accessible only to regional directors, study investigators
are further restricted to specific workstations with certificates of
authentication which are registered by the PI. Regional directors have
access to screens for requesting and obtaining on-line management
reports for their respective regions. Specialist investigators have access
only to their site investigators. Site investigators have access only to
their sites management reports.
The INVEST systems run Windows 95, Netscape 3.1 and IBM
Global Network software. It is recommended that all investigator sites
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operate with Internet access of 28.8K or higher running Netscape 3.1
or higher. Details regarding supported configurations are available at
the INVEST web site. A demo trial area is included for new investi-
gators. When authorized, new investigators use the demo area to test
their Internet connections and train on use of the on-line tools. Once
on-line training has been successfully completed, investigators are
authorized to enroll patients.
Computing platform. A SUN Microsystems Ultrasparc server
running Solaris 2.5 is used to provide web services to authorized users
over the Internet. The Ultrasparc also serves as a firewall and is
equipped with two Ethernet adapters to provide a private IP segment
for the database server running Oracle 7 on a Pentium Pro 180
machine under Windows NT 4.0.
Project software. Netscape Enterprise Server is used to respond to
all requests. Authorization is done in real-time against the manage-
ment database stored on a private IP network behind a firewall on the
Windows NT/Oracle server. Netscape Enterprise Server delivers high-
performance secure socket layer transactions using RSA 40 bit encryp-
tion. JavaScript is used to implement physician-side validation in
real-time of data entry attempts. Each field in all on-line forms is
checked in real-time for valid values. Only valid values are permitted
to pass into the data system. SAS (Statistical Analysis System) is used
to produce data summaries for management reports and statistical
analyses.
Internet connectivity. The servers are located in secure facilities at
the University of Florida and connected to the campus network via
10-megabit Ethernet. The campus network is routed via Cisco routers
and connected to a 45-megabit (T3) Internet Point of Presence (POP)
operated by BellSouth.
Backup. All Web site and database material are backed up on an
automated routine schedule using a 140-megabyte capacity automated
Exabyte tape library including twice-daily incremental backups and
once-a-week full system backups. Backup tapes are rotated daily to
secure off-site locations. The web server and the database server are
backed up separately to preserve system security.
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